Skip to main content
SpringerLink
Log in

Toxicogenomics in Biomarker Discovery

  • Protocol
Essential Concepts in Toxicogenomics

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 460))

Summary

In the area of toxicology, the subdiscipline of toxicogenomics has emerged, which is the use of genome-scale mRNA expression profiling to monitor responses to adverse xenobiotic exposure. Toxicogenomics is being investigated for use in the triage of compounds through predicting potential toxicity, defining mechanisms of toxicity, and identifying potential biomarkers of toxicity. Whereas various approaches have been reported for the development of algorithms predictive of toxicity and for the interpretation of gene expression data for deriving mechanisms of toxicity, there are no clearly defined methods for the discovery of biomarkers using gene expression technologies. Ways in which toxicogenomics may be used for biomarker discovery include analysis of large databases of gene expression profiles followed by in silico mining of the database for differentially expressed genes; the analysis of gene expression data from preclinical studies to find differentially expressed genes that correlate with pathology (coincident biomarker) or precede pathology (leading biomarker) within a lead series; or gene expression profiling can be performed directly on the blood from preclinical studies or clinical trials to find biomarkers that can be obtained noninvasively. This chapter broadly discusses the issues and the utility of applying toxicogenomics to biomarker discovery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. International Human Genome Sequencing Consortium. (2001) Nature 409, 860–921.

    Article  Google Scholar 

  2. Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J.,Sutton, G.G., et al. (2001) Science 291, 1304–1351.

    Article  CAS  PubMed  Google Scholar 

  3. Biomarkers Definitions Working Group. (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95.

    Google Scholar 

  4. Bailey, W.J. and Ulrich, R. (2004) Molecular profiling approachesfor identifying novel biomarkers. Expert Opin. Drug Saf. 3, 137–151.

    Article  CAS  PubMed  Google Scholar 

  5. Guerreiro, N., Staedtler, F., Grenet, O., Kehren, J., and Chibout,S.D. (2003) Toxicogenomics in drug development. Toxicol.Pathol. 31, 471–479.

    CAS  PubMed  Google Scholar 

  6. Feng, Z., Prentice, R.,and Srivastava, S. (2004) Research issuesand strategies for genomic and proteomic biomarker discovery andvalidation: a statistical perspective. Pharmacogenomics 5, 709–719.

    Article  CAS  PubMed  Google Scholar 

  7. Negm, R.S., Verma, M.,and Srivastava, S. (2002) The promise ofbiomarkers in cancer screening and detection. Trends Mol. Med.8, 288–293.

    Article  CAS  PubMed  Google Scholar 

  8. Goodsaid, F.M. (2004) Identification and measurement of genomicbiomarkers of nephrotoxicity. J. Pharmacol. Toxicol. Methods 49, 183–186.

    Article  CAS  PubMed  Google Scholar 

  9. Perazella, M.A. (2003) Drug-induced renal failure: update on newmedications and unique mechanisms of nephrotoxicity. Am. J.Med. Sci. 325, 349–362.

    Article  PubMed  Google Scholar 

  10. Templin, M.V., Jamison, K.C., Wolf, D.C., Morgan, K.T.,and Butterworth, B.E. (1996) Comparison of chloroform-induced toxicityin the kidneys, liver,and nasal passages of male Osborne-Mendel andF-344 rats. Cancer Lett. 104, 71–78.

    Article  CAS  PubMed  Google Scholar 

  11. Stacchiotti, A., Borsani, E., Rodella, L., Rezzani, R., Bianchi, R.,and Lavazza, A. (2003) Dose-dependent mercuric chloride tubularinjury in rat kidney. Ultrastruct. Pathol. 27, 253–259.

    Article  CAS  PubMed  Google Scholar 

  12. Stacchiotti, A., Lavazza, A., Rezzani, R., Borsani, E., Rodella, L.,and Bianchi, R. (2004) Mercuric chloride-induced alterations instress protein distribution in rat kidney. Histol.Histopathol. 19, 1209–1218.

    CAS  PubMed  Google Scholar 

  13. Kramer, J.A., Pettit, S.D., Amin, R.P., Bertram, T.A., Car, B.,Cunningham, M., et al. (2004) Overview on the application oftranscription profiling using selected nephrotoxicants fortoxicology assessment. Environ. Health Perspect. 112, 460–464.

    Article  CAS  PubMed  Google Scholar 

  14. Fernandez-Tome, M.C.,and Sterin-Speziale, N.B. (1994) Short- andlong-term treatment with indomethacin causes renal phospholipidalteration: a possible explanation for indomethacin nephrotoxicity.Pharmacology 48, 341–348.

    Article  CAS  PubMed  Google Scholar 

  15. Han, W.K., Bailly, V., Abichandani, R., Thadhani, R.,and Bonventre,J.V. (2002) Kidney Injury Molecule-1 (KIM-1): a novel biomarker forhuman renal proximal tubule injury. Kidney Int. 62,237–244.

    Google Scholar 

  16. Hewitt, S.M., Dear, J.,and Star, R.A. (2004) Discovery of proteinbiomarkers for renal diseases. J. Am. Soc. Nephrol. 15,1677–1689.

    Google Scholar 

  17. Rosenberg, M.E. and Silkensen, J. (1995) Clusterin: physiologic andpathophysiologic considerations. Int. J. Biochem. Cell. Biol.27, 633–645.

    Article  CAS  PubMed  Google Scholar 

  18. Drew, A.F., Tucker, H.L., Liu, H., Witte, D.P., Degen, J.L.,and Tipping, P.G. (2001) Crescentic glomerulonephritis is diminished infibrinogen-deficient mice. Am. J. Physiol. Renal Physiol. 281, F1157–1163.

    CAS  PubMed  Google Scholar 

  19. Amin, R.P., Vickers, A.E., Sistare, F., Thompson, K.L., Roman, R.J., Lawton, M., et al. (2004) Identification of putative gene basedmarkers of renal toxicity. Environ. Health Perspect. 112, 465–479.

    Article  CAS  PubMed  Google Scholar 

  20. Chevalier, R.L. (2004) Biomarkers of congenital obstructivenephropathy: past, present and future. J. Urol. 172,852–857.

    Article  PubMed  Google Scholar 

  21. Grenet, O., Varela, M.C., Staedtler, F.,and Steiner, S. (1998) Thecyclosporine A-induced decrease in rat renal calbindin-D28kDaprotein as a consequence of a decrease in its mRNA. Biochem.Pharmacol. 55, 1131–1133.

    Article  CAS  PubMed  Google Scholar 

  22. Krischer, J.P., Epstein, S., Cuthbertson, D.D., Goorin, A.M.,Epstein, M.L.,and Lipshultz, S.E. (1997) Clinical cardiotoxicityfollowing anthracycline treatment for childhood cancer. thepediatric oncology group experience. J. Clin. Oncol. 15,1544–1552.

    CAS  PubMed  Google Scholar 

  23. Keefe, D.L. (2002) Trastuzumab-associated cardiotoxicity. Cancer 95, 1592–1600.

    Article  CAS  PubMed  Google Scholar 

  24. Kruit, W.H., Punt, K.J., Goey, S.H., de Mulder, P.H., vanHoogenhuyze, D.C., Henzen-Logmans, S.C.,and Stoter, G. (1994)Cardiotoxicity as a dose-limiting factor in a schedule of high dosebolus therapy with \h{interleukin-2} and alpha-interferon. Anunexpectedly frequent complication. Cancer 74,2850–2856.

    Article  CAS  PubMed  Google Scholar 

  25. Alert for Healthcare Professionals Valdecoxib (marketed as Bextra).www.fda.gov/cder/drug/InfoSheets/HCP/valdecoxibHCP.htm.

  26. Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A.,and De Ponti,F. (2005) QT prolongation through hERG K(+) channel blockade:current knowledge and strategies for the early prediction duringdrug development. Med. Res. Rev. 25, 133–166.

    Article  CAS  PubMed  Google Scholar 

  27. Wallace, K.B., Hausner, E., Herman, E., Holt, G.D., MacGregor, J.T.,Metz, A.L., et al. (2004) Serum troponins as biomarkers ofdrug-induced cardiac toxicity. Toxicol. Pathol. 32,106–121.

    Article  CAS  PubMed  Google Scholar 

  28. Marian, A.J. and Nambi, V. (2004) Biomarkers of cardiac disease.Expert Rev. Mol. Diagn. 4, 805–820.

    Article  CAS  PubMed  Google Scholar 

  29. Kang, Y.J. (2001) Molecular and cellular mechanisms ofcardiotoxicity. Environ. Health Perspect. 109(Supp1) 27–34.

    Article  CAS  PubMed  Google Scholar 

  30. Schwartz, L., Boheler, K.R., De La Bastie, D., Lompre, A.M.,and Mercadier, J-J. (1992) Switches in cardiac muscle gene expresion asa result of pressure and volume overload. Am. J. Physiol. 262, R364–369.

    CAS  PubMed  Google Scholar 

  31. Rozich, J.D., Barnes, M.A., Schmid, P.G., Zile, M.R., McDermott,P.J.,and Cooper, G. (1995) Load effects on gene expression duringcardiac hypertrophy. J. Mol. Cell. Cardiol. 27,485–499.

    Article  CAS  PubMed  Google Scholar 

  32. Chien, K.R., Knowlton, K.U., Zhu, H.,and Chien, S. (1991)Regulation of cardiac gene expression during myocardial growth andhypertrophy: molecular studies of an adaptive physiologic response.FASEB J. 5, 3037–3046.

    CAS  PubMed  Google Scholar 

  33. Kolbeck-Ruhmkorff, C. and Zimmer, H.G. (1995) Proto-oncogeneexpression in the isolated working rat heart: combination ofpressure and volume overload with norepinephrine. J. Mol. Cell.Cardiol. 27, 501–511.

    Article  CAS  PubMed  Google Scholar 

  34. Lee, W.M. (2003) Drug-induced hepatotoxicity. N. Engl. J. Med.349, 474–485.

    Article  CAS  PubMed  Google Scholar 

  35. Park, B.K., Kitteringham, N.R., Maggs, J.L., Pirmohamed, M.,and Williams, D.P. (2005) The role of metabolic activation indrug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol.45, 177–202.

    Article  CAS  PubMed  Google Scholar 

  36. Kew, M.C. (2000) Serum aminotransferase concentration as evidence ofhepatocellular damage. Lancet 355, 591–592.

    Article  CAS  PubMed  Google Scholar 

  37. Kaplan, M.M. (2002) Alanine aminotransferase levels: what’s normal?Ann. Intern. Med. 137, 49–51.

    PubMed  Google Scholar 

  38. Bauer, I., Rensing, H., Florax, A., Ulrich, C., Pistorius, G., Redl, H.,and Bauer, M. (2003) Expression pattern and regulation of hemeoxygenase-1/heat shock protein 32 in human liver cells. Shock 20, 116–122.

    Article  CAS  PubMed  Google Scholar 

  39. Fang, C.W., Yao, Y.M., Shi, Z.G., Yu, Y., Wu, Y., Lu, L.R.,and Sheng, Z.Y. (2002) Lipopolysaccharide-binding protein andlipopolysaccharide receptor CD14 gene expression after thermalinjury and its potential mechanism(s). J. Trauma 53,957–967.

    Article  CAS  PubMed  Google Scholar 

  40. Flo, T.H., Smith, K.D., Sato, S., Rodriguez, D.J., Holmes, M.A., Strong, R.K., et al. (2004) Lipocalin 2 mediates an innate immuneresponse to bacterial infection by sequestrating iron. Nature 432, 917–921.

    Article  CAS  PubMed  Google Scholar 

  41. Petricoin, E.F., Zoon, K.C., Kohn, E.C., Barrett, J.C.,and Liotta,L.A. (2002) Clinical proteomics: translating benchside promise intobedside reality. Nat. Rev. Drug Discov. 1, 683–695.

    Article  CAS  PubMed  Google Scholar 

  42. Fan, H. and Hegde, P.S. (2005) The transcriptome in blood:challenges and solutions for robust expression profiling. Curr.Mol. Med. 5, 3–10.

    Article  CAS  PubMed  Google Scholar 

  43. Affymetrix Technical Note. (2003) An Analysis of Blood ProcessingMethods to Prepare Samples for GeneChip® Expression Profiling Santa Clara,

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biomarker Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

    Marc F. DeCristofaro

  2. Department of Toxicogenomics, Gene Logic Inc., Gaithersburg, Maryland

    Kellye K. Daniels

Authors
  1. Marc F. DeCristofaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kellye K. Daniels
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Gene Logic Inc, Gaithersburg, MD, USA

    Donna L. Mendrick

  2. The Critical Path Institute, Rockville, MD, USA

    William B. Mattes

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

DeCristofaro, M.F., Daniels, K.K. (2008). Toxicogenomics in Biomarker Discovery. In: Mendrick, D.L., Mattes, W.B. (eds) Essential Concepts in Toxicogenomics. Methods in Molecular Biology™, vol 460. Humana Press. https://doi.org/10.1007/978-1-60327-048-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-048-9_9

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-638-2

  • Online ISBN: 978-1-60327-048-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation